Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 52K
2: EX-99.1 Amended Stipulation and Agreement of Settlement HTML 230K
(Nov 2022)
3: EX-99.2 Notice of Pendency and Proposed Settlement of HTML 53K
Derivative Actions (Nov 2022)
8: R1 Cover Page Cover Page HTML 58K
11: XML IDEA XML File -- Filing Summary XML 12K
9: XML XBRL Instance -- mo-20221026_htm XML 38K
10: EXCEL IDEA Workbook of Financial Reports XLSX 8K
5: EX-101.DEF XBRL Definitions -- mo-20221026_def XML 44K
6: EX-101.LAB XBRL Labels -- mo-20221026_lab XML 95K
7: EX-101.PRE XBRL Presentations -- mo-20221026_pre XML 44K
4: EX-101.SCH XBRL Schema -- mo-20221026 XSD 15K
12: JSON XBRL Instance as JSON Data -- MetaLinks 15± 21K
13: ZIP XBRL Zipped Folder -- 0000764180-22-000112-xbrl Zip 124K
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i☐
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading Symbols
Name of each exchange on which registered
iCommon Stock, $0.33 1/3 par value
iMO
iNew
York Stock Exchange
i1.000% Notes due 2023
iMO23A
iNew
York Stock Exchange
i1.700% Notes due 2025
iMO25
iNew
York Stock Exchange
i2.200% Notes due 2027
iMO27
iNew
York Stock Exchange
i3.125% Notes due 2031
iMO31
iNew
York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
i☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01.Other Events.
On October 26, 2022, the United States District Court for the Eastern District of Virginia (the “Court”) entered an order granting preliminary
approval of the settlement of the shareholder derivative action captioned In re Altria Group, Inc. Derivative Litigation, Case No. 3:20-cv-00772-DJN (the “Federal Action”). The complaint in the Federal Action, as well as other related shareholder derivative actions pending in Virginia state courts (collectively with the Federal Action, the “Actions”), alleges various claims, including breach of fiduciary duty claims, against certain Altria Group, Inc. (“Altria”) current and former directors and officers relating to Altria’s investment in JUUL Labs, Inc. (“JLI”). The complaints in the Actions also allege various claims against JLI, its founders and some of its current and former executives. The Actions were resolved pursuant to an Amended Stipulation and Agreement of Settlement (the “Stipulation”), a copy of which is attached as Exhibit
99.1.
Pursuant to the Court’s order granting preliminary approval of the settlement, Altria is filing the Stipulation and the Notice of Pendency and Proposed Settlement of Derivative Actions (the “Notice”), a copy of which is attached as Exhibit 99.2, with the U.S. Securities and Exchange Commission, publishing a summary of the Notice in The Wall Street Journal and publishing the Stipulation and the Notice in the investors section of Altria’s website at www.altria.com/shareholdersettlement.
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.